Combating diseases through AI-based drug design

GenAI Driven Platform for Drug Design

We have created industry’s leading platform with integrated biology and pharmacology to design drugs at scale. The platform leverages Artificial Intelligence (AI), Machine Learning (ML) and GenAI models to design drugs that inhibit protein- protein interactions (PPi) that drive the pathological progression of serious diseases. Our ambition is to conquer and design drugs against 4000+ targets with known co-crustal structures to design and develop small molecular drugs that are orally available, safe and efficacious.

shape

ConquestBIO : De-risking Drug Design and Development leveraging AI

ConquestBio is a Drug Discovery and Development company registered in Delaware with operations in Florida. Conquest Bio was founded on the vision of applying a validated ML, AI and GenAI algorithms to mine the entire proteomic landscape to identify the most clinically validated druggable protein targets with no small molecules in development.

ConquestBio aims to apply structural biology, computational biology, AI, ML and GenAI to design and discover safe and efficacious small molecule drugs at an unprecedented scale, but at the same time derisking the enterprise by focusing on those molecular targets that have been validated biologically and clinically